Progress in Screening for Barrett's Esophagus: Beyond Standard Upper Endoscopy
Wei Keith Tan, Anamay N Sharma, Amitabh Chak, Rebecca C Fitzgerald, Wei Keith Tan, Anamay N Sharma, Amitabh Chak, Rebecca C Fitzgerald
Abstract
The rapid increase in the incidence of esophageal adenocarcinoma in Western populations over the past 4 decades and its associated poor prognosis, unless detected early has generated great interest in screening for the precursor lesion Barrett's esophagus (BE). Recently, there have been significant developments in imaging-based modalities and esophageal cell-sampling devices coupled with biomarker assays. In this review, the authors discuss the rationale for screening for BE and the factors to consider for targeting the at-risk population. They also explore future avenues for research in this area.
Keywords: Barrett’s esophagus; Esophageal adenocarcinoma; Screening.
Conflict of interest statement
Disclosure AC has founders shares and stock options in LucidDx, serves as a consultant to LucidDx, has sponsored research with LucidDx, and has a royalty interest in patents licensed by Case Western Reserve University to LucidDx. He is also a consultant for Interpace Diagnostics and receives research support from C2 Therapeutics/Pentax Inc. AC is supported by NIH grants U54 CA163060 and P50 CA150964. RCF is listed as an inventor on patents pertaining to Cytosponge and associated assays that have been licensed by the Medical Research Council to Civdien GI Solutions, now Medtronic. RCF has founders shares and serves as a consultant for Cyted Ltd. The laboratory of RCF is funded by a Core Programme Grant from the Medical Research Council (RG84369).
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed